Get key Q3 2025 earnings insights for Insulet (PODD): record revenue, robust growth in Type 1/Type 2 markets, upgraded guidance, and innovation updates.

Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...

Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...

Insulet Corporation recently reported strong third quarter results, with revenue and earnings surpassing analyst expectations and the company raising its full-year revenue and margin guidance. Key ...

Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling ...

Insulet stock shed its early gains Thursday, sliding into the red, despite broadly beating sales forecasts for its insulin ...

Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily ...

Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or ...

Insulet launches campaign inspired by the International Diabetes Federation’s focus on diabetes, well-being, and the workplace“The Day Diabetes Showed Up to Work” campaign recognizes the unique needs ...

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics ...

Insulet has launched a new campaign, “The Day Diabetes Showed Up to Work,” in honor of Diabetes Awareness Month in November.